Praxis Precision Medicines, Inc. (PRAX) - Dilution Analysis

10-Q filing | 28.9M shares outstanding

8-K filing: Praxis Precision Medicines, Inc. completed an underwritten offering of 2,212,000 shares of common stock at $260.00 per share, and the underwriters exercised their option to purchase an additional 331,800 shares, resulting in net proceeds of approximately $621.2 million. ($621.2M proceeds)

10-Q filing | 25.0M shares outstanding

8-K filing: Praxis Precision Medicines, Inc. terminated its 2024 sales agreement with Jefferies LLC and entered into a new sales agreement with TD Securities (USA) LLC. ($86.2M proceeds)

10-Q filing | 21.1M shares outstanding

10-K filing | 20.2M shares outstanding

10-Q filing | 18.9M shares outstanding

10-Q filing | 18.8M shares outstanding

10-Q filing | 17.1M shares outstanding

8-K filing: Praxis Precision Medicines, Inc. announced an underwritten offering of 3,318,585 shares of common stock and pre-funded warrants to purchase up to 221,238 shares, with underwriters exercising an option to purchase an additional 530,973 shares, resulting in expected net proceeds of approximately $215.6 million.

S-3 filing: Praxis Precision Medicines, Inc. is offering common stock, preferred stock, debt securities, warrants, and units up to an aggregate amount of $750,000,000 from time to time, including an "at the market offering" of common stock with an aggregate offering price of up to $150,000,000 through Jefferies as sales agent.

10-K filing | 13.2M shares outstanding

8-K filing: Praxis Precision Medicines, Inc. announced an underwritten offering of 3,168,275 shares of common stock and pre-funded warrants to purchase up to 1,056,725 shares, with the underwriters exercising their option to purchase an additional 633,750 shares, resulting in expected net proceeds of approximately $161.7 million.

8-K filing: Praxis Precision Medicines Inc. issued and sold 443,253 shares of common stock to BCPE Tenet Holdings Cayman, Ltd. at a price of $22.5605 per share for an aggregate purchase price of $10,000,009.31 as part of a Stock Purchase Agreement related to a collaboration and license agreement with Tenacia Biotechnology. ($10.0M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 135,591,429 → 9,039,428

10-Q filing | 135.6M shares outstanding

10-Q filing | 128.5M shares outstanding

8-K filing: Praxis Precision Medicines, Inc. announced an underwritten offering of 55,150,000 shares of common stock and pre-funded warrants to purchase 7,050,000 shares, with the underwriters exercising their option to purchase an additional 9,299,690 shares, resulting in expected net proceeds of approximately $63.3 million. ($63.3M proceeds)

10-Q filing | 62.1M shares outstanding

10-K filing | 52.4M shares outstanding

POS AM filing: Praxis Precision Medicines, Inc. files a POS AM for a mixed shelf offering of up to $300,000,000, including common stock, preferred stock, and debt securities. They are also offering common stock through an at-the-market offering.

10-Q filing | 45.8M shares outstanding

10-Q filing | 45.5M shares outstanding

10-Q filing | 45.5M shares outstanding

10-K filing | 42.5M shares outstanding

10-Q filing | 44.7M shares outstanding

10-Q filing | 41.6M shares outstanding

POS AM filing: Praxis Precision Medicines, Inc. is offering up to 5,750,000 shares of its Common Stock.

S-1 filing: Praxis Precision Medicines, Inc. is offering 4,000,000 shares of its common stock.

10-Q filing | 38.7M shares outstanding

10-K filing | 38.6M shares outstanding

10-Q filing | 1.7M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of common stock, with the underwriters having an option to purchase additional shares.

S-1/A filing: This S-1/A filing describes an offering of common stock, including an underwriter option to purchase additional shares, with the proceeds intended to create a public market, increase visibility, and fund clinical trials and other corporate purposes.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.